Potential of Zn Doped Silicon and Carbon Nanostructures for Triazavirin Delivery as Effective Drug of Coronavirus Disease
Source abstract
Abstract
In this study, the performances of Zn-doped nanotubes and Zn-doped nanocages to delivery of Triazavirin as drugs of Coronavirus disease is examined. The ΔGadsorption and recovery time for complexes of Triazavirin with Zn-C48, Zn-Si48, Zn-CNT (5, 0) and Zn-SiNT (5, 0) are calculated by theoretical methods. The ΔGadsorption of complexes of b, d, f, h including the Triazavirin-Zn-C48, Triazavirin-Zn-Si48, Triazavirin-Zn-CNT (5, 0) and Triazavirin-Zn-SiNT (5, 0) in water are -3.46, -3.61, -4.28 and -4.40 eV, respectively. The τ of complexes of b, d, f, h including the Triazavirin-Zn-C48, Triazavirin-Zn-Si48, Triazavirin-Zn-CNT (5, 0) and Triazavirin-Zn-SiNT (5, 0) in water are 55.16, 58.52, 62.06 and 67.07 s respectively. Finally, the Zn-SiNT (5, 0) and Zn-CNT (5, 0) have high potential to Triazavirin delivery and these nano-structures can propose to use as deliver of important drugs of Coronavirus disease.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Viral gastroenteritis research and epidemiology · Animal Virus Infections Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Cucinotta D, Vanelli M (2020) Acta Biomed 91:157–160
2. Zhou P, Yang XL, Wang XG, Hu B (2020) Nature 579:270–27310.1038/s41586-020-2012-7 ↗
3. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y (2019) Viruses 11:5910.3390/v11010059 ↗
4. Cui J, Li F, Shi Z-L (2019) Nat Rev Microbiol 17:181–19210.1038/s41579-018-0118-9 ↗
5. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X (2020) Nat Rev Cardiol 17:259–26010.1038/s41569-020-0360-5 ↗
6. Bangash MN, Patel J, Parekh D (2020) Lancet Gastroenterol Hepatol 5:529–53010.1016/S2468-1253(20)30084-4 ↗
7. Zhang C, Shi L, Wang F-S (2020) Lancet Gastroenterol Hepatol 5:428–43010.1016/S2468-1253(20)30057-1 ↗
8. Razavi R, Amiri M, Niasari M (2021) Arabian J Chem 14:10332310.1016/j.arabjc.2021.103323 ↗
9. Shemshadi R, Razavi R, Parsaee Z (2018) Catal Today 335:582–590
10. Ghorbani S, Razavi R, Alhaji A (2017) J Cluster Sci 28:1523–153910.1007/s10876-017-1162-8 ↗
11. Sarafbidabad M, Razavi R (2018) New J Chem 42:13674–1368310.1039/C8NJ01796D ↗
12. Mir M, Razavi R, Baghban A (2018) Petrol Sci Techn 36:1022–102910.1080/10916466.2018.1458123 ↗
13. Rothan HA, Byrareddy SN (2020) J Autoimmun 109:10243310.1016/j.jaut.2020.102433 ↗
14. Heymann DL, Shindo N (2020) Lancet 395:542–54510.1016/S0140-6736(20)30374-3 ↗
15. Guest MF, Bush IJ (2005) Mol Phys 103:719–74710.1080/00268970512331340592 ↗
16. Ozolins V, Körling M (1993) Phys Rev B 48:18304–1830710.1103/PhysRevB.48.18304 ↗
17. Csonka GI, Perdew JP, Ruzsinszky A (2009) Phys Rev B 79:15510710.1103/PhysRevB.79.155107 ↗
18. Perdew JP, Chevary JA (1992) Phys Rev B 46:6671–668710.1103/PhysRevB.46.6671 ↗
19. Söderlind P, Gonis A (2010) Phys Rev B 82:03310210.1103/PhysRevB.82.033102 ↗
20. Masters PS (2006) Adv Virus Res 66:193–29210.1016/S0065-3527(06)66005-3 ↗
21. Song X, Li Q, Zhang J (2023) Biomed Pharmacother 162:11461110.1016/j.biopha.2023.114611 ↗
22. Wang Y, Zhai W, Li J, Liu H, Li J (2023) Tribol Int 188:10889110.1016/j.triboint.2023.108891 ↗
23. Hu F, Qiu L, Xia W, Liu C, Xi X, Su N (2022) Front. Public Health 10:949482
24. Wang Y, Li C, Shen B, Zhu L, Jiang L (2023) Chem Eng J 466:14329210.1016/j.cej.2023.143292 ↗
25. Dong L, Gan L, Wang H, Cai W (2019) Int Medical J Exp Clinical Res 25:5127–5136
26. Wang D, Wang X, Peng X, Xin H (2018) Cancer Gene Ther 25:93–10510.1038/s41417-018-0016-3 ↗
27. Yu T, Xu B, Bao M, Gao Y, Zhang Q, Liu R (2022) Front Endocrinol 13:98110010.3389/fendo.2022.981100 ↗
28. Guo Z, Wang Y, He B, Zhou J, Chiarla C (2022) Dis Markers 2022:6707821
29. Wu J, Fang Z, Wang X, Zeng W (2022) Horm Res Paediatr 95:384–39210.1159/000525769 ↗
30. Gao Y, Liu Y, Liu Y, Peng Y, Yuan B, Li X (2021) Cancer Lett 520:172–18310.1016/j.canlet.2021.07.012 ↗
31. He B, Hou F, Ren C, Bing P, Xiao X (2021) Front Oncol 11:71122510.3389/fonc.2021.711225 ↗
32. Shen X, Sun Y, Zhang Y (2021) Workshop on Natural Language Process. Convers 1:120-129
33. Ma W (2022) Research Posters. Columbus, Ohio, USA, ASME. 1, V009T12A020
34. Yang F, Shao C (2022) Emergency Management Science and Technology 2:110.48130/EMST-2022-0018 ↗
35. Shahrani M, Rajagopalan P, Abohassan M, Alraey Y (2021) Oncol Res 29:149–15710.32604/or.2022.03539 ↗